Page last updated: 2024-08-25

strictinin and ER-Negative PR-Negative HER2-Negative Breast Cancer

strictinin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baird, N; Chen, B; Fultang, N; Illendula, A; Jonnalagadda, S; Klase, Z; Peethambaran, B; Wu, C	1

Other Studies

1 other study(ies) available for strictinin and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity. PloS one, 2019, Volume: 14, Issue:5 Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; Oncogene Protein v-akt; Phenols; Phosphatidylinositol 3-Kinases; Phosphorylation; Receptor Tyrosine Kinase-like Orphan Receptors; Signal Transduction; Triple Negative Breast Neoplasms	2019

Article

Year

Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.

PloS one, 2019, Volume: 14, Issue:5

Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; Oncogene Protein v-akt; Phenols; Phosphatidylinositol 3-Kinases; Phosphorylation; Receptor Tyrosine Kinase-like Orphan Receptors; Signal Transduction; Triple Negative Breast Neoplasms

2019